featured
2022 Top Story in Oncology: Immunotherapy for the First-Line Treatment of Metastatic/Recurrent NSCLC
Written by
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Brahmer JR, Lee J, Ciuleanu T, et al. Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer in CheckMate 227. J Clin Oncol. 2022 Oct 12. Doi: 10.1200/JCO.22.01503. Online ahead of print.
- de Castro G Jr, Kudaba I, Wu YL, et al. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study. J Clin Oncol. 2022 Oct 28. Doi: 10.1200/JCO.21.02885. Online ahead of print.
- Johnson ML, Cho BC, Luft A, et al. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study. J Clin Oncol. 2022 Nov 3. Doi: 10.1200/JCO.22.00975. Online ahead of print.
- Spigel DR, Faivre-Finn C, Gray JE, et al. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022 Apr 20;40(12):1301-1311.
- Douillard J-Y. Five-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC [abstract of Spigel R, Faivre-Finn C, Gray JE, et al. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022. 20;40(12):1301-1311]. PracticeUpdate Lung Cancer. 2022 Feb 17. Accessed November 17, 2022.
- Forde PM, Spicer J, Lu S, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022;386(21):1973-1985.
- Douillard J-Y. Neoadjuvant Nivolumab Plus Chemotherapy in Resectable Lung Cancer [abstract of Forde PM, Spicer J, Lu S, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022;386(21):1973-1985]. PracticeUpdate Lung Cancer. 2022 May 3. Accessed November 17, 2022.
- Provencio M, Serna-Blasco R, Nadal E, et al. Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial). J Clin Oncol. 2022;40(25):2924-2933.